70%
Of GLP-1 users report side effects that impact their daily life.[1]
About Us
Extending care beyond the clinic
We’re on a mission to ensure every GLP-1 user receives personalized support to achieve lasting health outcomes, while helping reduce provider burden and burnout.
Our Mission
Supporting providers and patients in chronic care
Alnu Health was founded with a clear mission: to help care teams and patients succeed in chronic care through clinically grounded, personalized support that drives durable outcomes.
We work alongside leading physicians, dietitians, and researchers from institutions including Harvard Medical School and Massachusetts General Hospital to build practical tools that close real-world care gaps. This includes helping patients manage side effects, maintain nutrition, and preserve lean mass over time.
We believe medication is only one part of successful long-term care. By combining clinical expertise with personalized coaching and tracking, we support providers in delivering consistent, high-quality follow-up and help patients stay engaged, feel better, and achieve meaningful outcomes.
We are starting with the GLP-1 community, where patients and care teams often need more support between visits to sustain progress over time.
50-68%
Discontinue treatment within a year before reaching their goals.[2-4]
Our Values
What drives us
Every decision we make is guided by our commitment to patients, clinical excellence, and data security.
Clinically-Backed
Built with leading clinicians from Harvard Medical School, Massachusetts General Hospital, and Weill Cornell. Every feature is grounded in clinical evidence.
Patient-Centered
Designed around the patient experience. We listen to real GLP-1 users and build tools that address their actual needs and challenges.
Data Security
Your health data deserves the highest protection. We are HIPAA compliant to ensure your information stays safe and private.
Our Advisors
World-class guidance
Dr. Florence Porterfield, MD
Obesity Medicine Clinical Advisor
Drew Young
Obesity Medicine Commercial Advisor
Dr. Bryn Falahee, MD
Obesity Medicine & Gastroenterology
In the News
News & Resources
Links to news articles about Alnu Health and GLP-1 treatments.
Nature Medicine
The Long-Term Effects of GLP-1 Receptor Agonists on Weight Management
JAMA Network Open
Discontinuation and Reinitiation of GLP-1 Receptor Agonists
Obesity (Silver Spring)
Nutritional Priorities to Support GLP-1 Therapy for Obesity
Diabetes, Obesity and Metabolism
Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide
Get Started
Ready to transform patient engagement?
Join the Alnu Health community and bring personalized GLP-1 support to your practice or your patients.